Show simple item record

dc.contributor.authorSigurdsson, Bjarki
dc.contributor.authorSigurdardottir, Ragna
dc.contributor.authorArnardottir, Margret B
dc.contributor.authorLund, Sigrun H
dc.contributor.authorJonasson, Jon G
dc.contributor.authorBjörnsson, Einar S
dc.date.accessioned2021-01-22T12:11:00Z
dc.date.available2021-01-22T12:11:00Z
dc.date.issued2020-10-14
dc.date.submitted2021-01
dc.identifier.citationSigurdsson B, Sigurdardottir R, Arnardottir MB, Lund SH, Jonasson JG, Björnsson ES. A nationwide study on hepatocellular carcinoma. Cancer Epidemiol. 2020 Dec;69:101835. doi: 10.1016/j.canep.2020.101835.en_US
dc.identifier.pmid33068877
dc.identifier.doi10.1016/j.canep.2020.101835
dc.identifier.urihttp://hdl.handle.net/2336/621643
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractBackground & aims: Population based studies on the epidemiology of HCC are scarce. We aimed to compare CG (cirrhotic HCC group) with NCG (non-cirrhotic HCC group), analyze incidence, etiology and survival among patients diagnosed in Iceland in a population-based cohort. A previous study from Iceland (1984-1998) showed an incidence of HCC of 1.1/100.000, mostly with NCG. Methods: A nationwide, population based retrospective study. Information on patients with HCC during 1998-2017 was obtained and medical records viewed. Results: Overall 152 patients with HCC were identified. The mean incidence was 1.7/100.000 and increased by 8% annually. Alcohol and hepatitis C combined was more common as a risk factor in CG than in the NCG (13 % vs. 2%, p = 0.03). Tumor size was larger in NCG (11 cm vs 5 cm, p < 0.01) and portal vein thrombosis less common (11 % vs. 30 %, p = 0.03). Overall, 44 % in NCG underwent surgical treatment vs. 23 % in CG (p = 0.02). The proportion of patients diagnosed by surveillance in 1998-2007 was 3% and 19 % in 2008-2017 (p = 0.03). The disease specific median survival for cirrhotic patients diagnosed by surveillance was 519 days and 86 days in other cirrhotic patients, hazard ratio 0.45 (p = 0.007, CI 0.25-0.81). Conclusions: A major increase in the incidence of patients with HCC has occurred. The non-cirrhotic HCC presented with larger size tumors, lower proportion of portal vein thrombosis and were more likely to be surgical candidates, although not affecting prognosis. Diagnosis by surveillance in patients with cirrhosis has increased and the survival of those patients is better compared to others. Keywords: Cirrhosis; Epidemiology; Hepatocellular carcinoma; Non-cirrhotic etiology.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S1877782120301697en_US
dc.rightsCopyright © 2020 Elsevier Ltd. All rights reserved.
dc.subjectCirrhosisen_US
dc.subjectEpidemiologyen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectNon-cirrhotic etiologyen_US
dc.subjectLifrarkrabbameinen_US
dc.subjectKrabbameinen_US
dc.subjectLifuren_US
dc.subjectSkorpulifuren_US
dc.subject.meshCarcinoma, Hepatocellularen_US
dc.titleA nationwide study on hepatocellular carcinoma.en_US
dc.typeArticleen_US
dc.identifier.eissn1877-783X
dc.contributor.department1Department of Gastroenterology and Hepatology, Landspitali University Hospital, Hringbraut, 101, Reykjavik, Iceland; Department of Pathology, Landspitali University Hospital, Hringbraut, 101, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland. Electronic address: bjs270292@gmail.com. 2Department of Gastroenterology and Hepatology, Landspitali University Hospital, Hringbraut, 101, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland. Electronic address: ragnasi@landspitali.is. 3Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland. Electronic address: margretbjort9@gmail.com. 4Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland; Decode Genetics, Sturlugata 8, 101, Reykjavik, Iceland. Electronic address: sigrunhelga@gmail.com. 5Department of Pathology, Landspitali University Hospital, Hringbraut, 101, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland. Electronic address: jongj@landspitali.is. 6Department of Gastroenterology and Hepatology, Landspitali University Hospital, Hringbraut, 101, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland. Electronic address: einarsb@landspitali.is.en_US
dc.identifier.journalCancer epidemiologyen_US
dc.rights.accessNational Consortium - Landsaðganguren_US
dc.departmentcodeGAS12
dc.departmentcodePTT12
dc.source.journaltitleCancer epidemiology
dc.source.volume69
dc.source.beginpage101835
dc.source.endpage
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record